| Pathogenesis of psoriasis and development of treatment |
59 |
| pH in nature, humans and skin |
34 |
| Systemic sclerosis |
26 |
| Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase multicenter, open-label study |
21 |
| Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase randomized, double-blind, placebo-controlled study |
17 |
| Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial |
16 |
| Safety of biologics in psoriasis |
16 |
| Clinical practice guidelines for the management of atopic dermatitis 2018 |
15 |
| Burden of atopic dermatitis in Japanese adults: Analysis of data from the 2013 National Health and Wellness Survey |
13 |
| Terbinafine-resistant strain of Trichophyton interdigitale strain isolated from a tinea pedis patient |
12 |
| HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy |
12 |
| Impact of chronic urticaria on quality of life and work in Japan: Results of a real-world study |
11 |
| Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience |
11 |
| Cancer risk in 892 089 patients with psoriasis in Korea: A nationwide population-based cohort study |
10 |
| Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease |
10 |
| Immunological dysfunction in chronic arsenic exposure: From subclinical condition to skin cancer |
9 |
| Immune reconstitution inflammatory syndrome in non-HIV immunosuppressed patients |
9 |
| Epidemiology and comorbidities of patients with chronic urticaria in Korea: A nationwide population-based study |
9 |
| Diagnostic criteria, severity classification and guidelines of localized scleroderma |
9 |
| Treatment outcome and prognostic factors of tonsillectomy for palmoplantar pustulosis and pustulotic arthro-osteitis: A retrospective subjective and objective quantitative analysis of 138 patients |
9 |
| Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls |
9 |
| Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study |
9 |
| Claudin reduction may relate to an impaired skin barrier in rosacea |
9 |
| Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study |
8 |
| Systematic review of the prevalence of nodal metastases and the prognostic utility of sentinel lymph node biopsy in cutaneous squamous cell carcinoma |
8 |
| Relationship between rosacea and dietary factors: A multicenter retrospective case-control survey |
8 |
| Phenotypes of atopic dermatitis identified by cluster analysis in early childhood |
8 |
| Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits |
8 |
| Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid |
8 |
| Profile of the skin microbiota in a healthy Chinese population |
8 |
| Real-world use of apremilast for patients with psoriasis in Japan |
8 |
| Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis |
8 |
| Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: A systematic meta-analysis |
8 |
| Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita) |
8 |
| Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open-label phase 3 study |
8 |
| Clinical and molecular implications of structural changes to desmosomes and corneodesmosomes |
8 |
| Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance |
7 |
| Demographic and clinical features of hidradenitis suppurativa in Korea |
7 |
| Trichoscopy of alopecia areata: An update |
7 |
| Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis |
7 |
| Japanese Dermatological Association Guidelines: Guidelines for the treatment of acne vulgaris 2017 |
7 |
| Mouse models of psoriasis and their relevance |
7 |
| Effects of tumor necrosis factor interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis |
7 |
| Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis |
7 |
| Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study |
7 |
| Efficacy of long-term treatment with efinaconazole 10% solution in patients with onychomycosis, including severe cases: A multicenter, single-arm study |
6 |
| Ustekinumab treatment for hidradenitis suppurativa |
6 |
| Patient preference for biologic treatments of psoriasis in Japan |
6 |
| Increased interleukin-36 expression in skin and sera of patients with atopic dermatitis and mycosis fungoides/Sezary syndrome |
6 |
| Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study |
6 |
